PerkinElmer, Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Prahlad R. Singh
- Full Time Employees
- 16,700
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 940 Winter Street Waltham MA United States of America 02451
- IPO Date
- Apr 6, 1983
- CIK
- 0000031791
- Website
- perkinelmer.com
- Similar Companies
- Business
- PerkinElmer, Inc. (NYSE: PKI) provides end-to-end solutions in diagnostics, life sciences, and applied markets, including advanced technologies, reagents, assays, instruments, automation, informatics, and services that support disease diagnosis, drug discovery, environmental monitoring, food safety, and industrial analysis. The company operates through two primary segments: Diagnostics, which offers genetic screening platforms such as GSP, molecular diagnostics, infectious disease testing including PCR reagents and immunoassays for bacteria, viruses, and parasites, autoimmune testing across rheumatology, neurology, and other areas, and newborn screening solutions like Specimen Gate; and Discovery & Analytical Solutions (following the 2023 divestiture of Applied, Food, and Enterprise Services to New Mountain Capital for $2.45 billion), which delivers radiometric detection including Tri-Carb liquid scintillation analyzers and radiochemicals, AlphaScreen and luminescence assays, recombinant cell lines for GPCR and ion channels, BioLegend ELISA kits, chromatography systems like LC 300 UHPLC and GC columns, atomic and molecular spectroscopy instruments, thermal analysis tools, and OneSource laboratory services. PerkinElmer serves pharmaceutical, biopharma, academic, government, healthcare, environmental, food, forensics, and industrial customers in approximately 190 countries. In November 2025, PerkinElmer acquired Project Farma, a life sciences consultancy from Precision for Medicine, to expand OneSource professional services in project management, validation, quality compliance, and engineering for GMP facilities and drug development acceleration. Founded in 1937 and headquartered in Shelton, Connecticut, the company employs over 16,000 people globally and maintains key facilities in the US, Europe (including Germany and UK), Asia-Pacific (such as China and Shanghai), with a focus on innovation in healthcare technology and life science tools.
Parkland (TSE:PKI) Stock Price Crosses Above 200 Day Moving Average – Should You Sell?
AUTOCRYPT Achieves WebTrust Accreditation for V2X PKI Infrastructure
WD Advances Next-Generation Trusted Infrastructure with Industry's First Post-Quantum Cryptography Hard Drives to Help Secure the Future of AI Data
Parkland (TSE:PKI) Stock Passes Above 200 Day Moving Average – Here’s What Happened
New Research Shows That Legacy PKI Puts Digital Identities at Risk, With 56% of Organizations Experiencing Services Disruption
Parkland (TSE:PKI) Stock Price Passes Above Two Hundred Day Moving Average – Here’s What Happened
Parkland (TSE:PKI) Stock Price Crosses Above 200-Day Moving Average – Time to Sell?
Parkland (TSE:PKI) Stock Price Crosses Above Two Hundred Day Moving Average – Time to Sell?
Parkland Corporation anuncia la finalización de la adquisición por Sunoco LP
Keyfactor Unlocks Digital Trust with Integrations for Advanced PKI & Certificate Automation in ServiceNow
Real World Evidence (RWE) Oncology Market to Reach $3.51 Billion by 2035, Growing at a CAGR of 14.7% from 2025--Exclusive Report by Meticulous Research®
PerkinElmer Acquires Project Farma, Expanding Its OneSource Professional Services Offering for the Life Sciences Industry
WISeKey PKI and SEALSQ Post-Quantum Technologies Enhance E-Voting Security through Advanced Cybersecurity and AI Integration
Climb Channel Solutions Announces Keyfactor as New North American Channel Partner
PARKLAND ANNOUNCES PRICING OF SENIOR UNSECURED NOTES OFFERING
PARKLAND ANNOUNCES US$500 MILLION OFFERING OF SENIOR UNSECURED NOTES
AppViewX Recognized by Outstanding Security Performance Awards 2024
PerkinElmer Acquires Covaris to Create an Innovation-Led, Global Life-Sciences and Diagnostics Platform
Parkland appoints Nora Duke to its Board of Directors
PerkinElmer (PKI) Q1 Earnings Surpass Estimates